10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
24 line items · 2 periods
XBRL
| Item | Jun 30, 2025 | Dec 31, 2024 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 5,914,980 | 3,750,525 |
Prepaid expenses and other current assets | 163,647 | 308,239 |
Total Current Assets | 6,078,627 | 4,058,764 |
Intangible assets, net | 3,066 | 3,348 |
Equity method investment | 720,010 | 981,830 |
Equity Method Investments | 720,010 | 981,830 |
Total Assets | 6,801,703 | 5,043,942 |
Current Liabilities: | ||
Accounts payable | 671,118 | 250,130 |
Related Party | — | 48,272 |
Accrued expenses | 539,909 | 677,456 |
Total Current Liabilities | 1,211,027 | 975,858 |
Total Liabilities | 1,211,027 | 975,858 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 21,534,695 and 6,474,588 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 21,535 | 6,473 |
Additional paid in capital | 91,751,821 | 86,056,934 |
Pre Funded Warrants | 3,300,000 | — |
Accumulated deficit | (86,182,680) | (81,995,323) |
Total Stockholders’ Equity | 5,590,676 | 4,068,084 |
Common Stock | 21,535 | 6,473 |
Additional Paid In Capital | 91,751,821 | 86,056,934 |
Accumulated Deficit | (86,182,680) | (81,995,323) |
Total Liabilities and Stockholders’ Equity | 6,801,703 | 5,043,942 |